title: Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
authors.forename: Florence
authors.initials: F
authors.lastname: Damond
authors.forename: Sophie
authors.initials: S
authors.lastname: Matheron
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Pauline
authors.initials: P
authors.lastname: Campa
authors.forename: Audrey
authors.initials: A
authors.lastname: Taieb
authors.forename: Gilles
authors.initials: G
authors.lastname: Collin
authors.forename: Christophe
authors.initials: C
authors.lastname: Delaunay
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Françoise
authors.initials: F
authors.lastname: Brun-Vézinet
authors.forename: Diane
authors.initials: D
authors.lastname: Descamps
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005602:France; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase; D015498:HIV-2 / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D012194:RNA-Directed DNA Polymerase / Q000235:genetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068698:Tenofovir; D013997:Time Factors
chemical_list: D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; C072416:reverse transcriptase, Human immunodeficiency virus 2; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D000225:Adenine